Form 6-K BioLineRx Ltd. For: Aug 20
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Roth Capital Affirms BioLineRx (BLRX) at 'Buy' Following Q2 Results; BL-8040 Continues to be Main Driver
August 20, 2015 12:40 PM EDTRoth Capital affirms BioLineRx (NASDAQ: BLRX) with a Buy rating and $7 price target after BLRX reported quarterly results earlier Thursday.
BLRX posted Q2 EPS of ($0.12), which was $0.04 worse than the analyst estimate of ($0.08).
Analyst Joseph Pantginis offered the following commentary, We currently view BL-8040 as the main value driver for the company with multiple near-term milestones expected. The most significant... More
BioLineRx (BLRX) Misses Q2 EPS by 4c
August 20, 2015 7:05 AM EDTBioLineRx (NASDAQ: BLRX) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08).
For earnings history and earnings-related data on BioLineRx (BLRX) click here.
... More